Peptide Synthesis Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

Peptide Synthesis Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

The peptide synthesis market is expected to register a CAGR of 5.5% over the forecast period (2022-2027).

Peptides were increasingly being developed and repurposed in search of therapeutics for the treatment of COVID-19. For instance, as per the August 2022 update from Clinical Trials.gov, more than 100 peptide drugs are in development for the treatment of COVID-19, including 15 synthetic peptides for acute respiratory distress syndrome (ARDS), a life-threatening condition where the lungs cannot provide the body’s vital organs with enough oxygen, and other respiratory illnesses caused by SARS-Cov-2 infection. Additionally, the article published in 2022 under the title "Peptide-Based Vaccines and Therapeutics for COVID-19" stated that because of the urgent need for alternative COVID-19 therapy peptides are found to be useful due to their target selectivity, improved interactions, and reduced toxicity. Peptides' quick metabolism can be slowed down and given long-acting properties with minor structural changes. Hence as per the information quoted above, COVID-19 had a significant impact on the peptide synthesis market.

The major growth of the market is a steep rise in the adoption of peptides in the pharmaceutical and consumer healthcare industries. The peptides have a wide range of applications in the treatment of various lifestyle disorders, such as cancers, diabetes, and obesity. The increasing incidence of these metabolic and lifestyle disorders is paving the way for the application of peptide therapeutics in oncology and metabolic disorders. For instance, according to the International Diabetes Federation statistics published in 2021, 537 million adults (20-79 years) were living with diabetes globally. This constituted 1 in 10 people affected with diabetes. As per the same source, 541 million adults have Impaired Glucose Tolerance (IGT), which places them at high risk of type 2 diabetes. Several peptide therapies, such as Glucagon-like peptide-1amide, release postprandially that stimulates insulin secretion, and they are popular in pancreatic therapy. As a result, the demand for peptide drugs are anticipated to rise as the number of diabetic patients grows, which is likely to drive the market throughout the forecast period.

The increased research activities and novel product approvals due to the rise in funding for research and development and the advantages of advanced peptide synthesizers have further boosted the growth of the peptide synthesis market throughout the period. For instance, in April 2021, ISSAR Pharma announced that they were licensing their peptide-based New Chemical Entities (NCEs), with pre-investigational new drug (IND) filing and the United States patent. Thus, such significant developments in peptide drugs are expected to boost the market demand.

However, the issues about large-scale peptide synthesis and the lack of a robust distribution network restrain the market growth over the forecast period.

Key Market TrendsPharmaceutical and Biotechnology Companies are Expected to Hold a Significant Market Share Over the Forecast Period

The research and developments of peptide therapies are increasing, as they are cost-effective, efficient, and have lower toxicity. The major factor driving the market for peptide synthesis in pharmaceutical and biotechnology companies is rapid technological advancements in peptide synthesizers and a strong peptide therapeutics pipeline. For instance, the article published in Science Direct in 2022 under the title “Advances in oral peptide drug nanoparticles for diabetes mellitus treatment” stated that a promising approach to treating diabetes mellitus is through oral administration of peptide medications. In comparison to parenteral administration methods, oral administration of peptide medicines is found to be a potential approach for the treatment of diabetes mellitus due to its ease and high patient compliance.

Product launches, mergers, and acquisitions presence of competitors are boosting the market growth. For instance, in January 2022, Novo Nordisk India launched the world’s first ‘Peptide In A Pill’ for diabetes management. The peptide named, Semaglutide, a GLP-1 receptor analog (GLP-1 RA), is one of the drug classes for the management of type 2 diabetes. All these developments are expected to propel the growth of the pharmaceutical and biotechnology end-user segment in the peptide synthesis market.

North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to dominate the overall peptide synthesis market throughout the forecast period. The dominance is due to the growing prevalence of obesity with a rise in sedentary deskbound lifestyles, and lack of proper diet and physical activity resulting in various chronic diseases like diabetes in the United States necessitating efficient treatment. For instance, according to the International Diabetic Federation 2021 report, an estimated 51 million adults aged 20-29 years were living with diabetes in the North America Caribbean (NAC) region in 2021, representing a regional prevalence of 14.6%. This region has the second highest number of children and adolescents with type 1 diabetes (193,000). The high prevalence of diabetes is expected to continue resulting in higher demand for peptide therapeutics driving the market in the studied region.

Furthermore, the increased availability of advanced healthcare infrastructure and huge investments by the key players in this region to develop new peptide synthesis technologies are also likely to fuel the market growth. For instance, in 2020 the United States Food and Drug Administration (US FDA) approved Imcivree (setmelanotide), a pro-opiomelanocortin-derived peptide for chronic weight management (weight loss and weight maintenance for at least one year) in patients for six years and older with obesity due to rare genetic conditions. Accelerated drug approval initiative by the US FDA is also likely to fuel the market growth in this region across the forecast period, contributing to its outstanding market share in the global peptide synthesis market.

Competitive Landscape

The peptide synthesis market is moderately competitive, with several major players. Some companies are expanding their market position by adopting various strategies, such as acquisitions, mergers, and research collaborations, while others are introducing new products to maintain their market share. A few of the major players currently dominating the industry in terms of revenue are AAPPTec, CSBio Company Inc., Biotage, Bachem Holding AG, and CEM Corporation.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.